Journal of Clinical Toxicology
Open Access

Firouzeh Asadi

Publications

• Research Article
  Pretreatment of CAV Combination Chemotherapy with Tropisetron Shows Less Cardio and Neurotoxicity Side Effects in Rats
  Author(s): Houman Alimoradi, Anita Barzegar-Fallah, Sanaz Mohammadi-Rick, Firouzeh Asadi, Bahram Delfan and Ahmad Reza DehpourHouman Alimoradi, Anita Barzegar-Fallah, Sanaz Mohammadi-Rick, Firouzeh Asadi, Bahram Delfan and Ahmad Reza Dehpour
  
  Tropisetron, a 5-HT3 antagonist receptor, is commonly used for the prevention of emesis following chemotherapy. Lines of evidence point to the anti-inflammatory and immune modulatory properties of tropisetron. The current study aims to investigate whether tropisetron is able to prevent the cardiotoxicity and neurotoxicity induced by doxorubicin (DOX) and vincristine besides its anti emetic effect in a co-administration protocol, since this combination therapy is widely used in various combination chemotherapy regimens. To investigate these effects, intraperitoneal co-administration of doxorubicin and vincristine in CAV combination therapy (Cyclophosphamide, Adriamycin and Vincristine) was used to induce neuro and cardiotoxicity and in treated group tropisetron was injected 1 h prior to combination therapy. General conditions, mortality rate and body weight were measured during the exp.. View More»
  DOI: 10.4172/2161-0495.S6-001

  Abstract PDF

Relevant Topics